A Phase III Trial of Continuous Low-Dose Infusion versus Intermittent High-Dose Infusion of 5-Fluorouracil in Patients with Disseminated Colorectal Cancer

Osteoporosis in Colorectal Cancer Survivors: Analysis of the Linkage between SWOG Trial Enrollees and Medicare Claims

A Barzi;D Hershman;C Till;W Barlow;S Ramsey;H-J Lenz;H Hochster;J Unger Archives of Osteoporosis Jul 28;14(1):83

PMid: PMID31352608 | PMC number: PMC6852789

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials

H Greenlee;J Unger;M Leblanc;S Ramsey;D Hershman Cancer Epidemiology Biomarkers & Prevention 2017 Jan;26(1):21-29; 2016 Dec 16. [Epub ahead of print]

PMid: PMID27986655 | PMC number: PMC5370550

Patterns of osteoporosis (OP) in survivors of colorectal cancer (CRC) enrolled on SWOG trials

A Barzi;D Hershman;C Till;H Lenz;H Hochster;W Barlow;J Unger J Clin Oncol 35, 2017 (suppl; abstr 10056); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session

Association between BMI at treatment initiation and cancer survival across multiple SWOG trials

H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster

Assessment of infusional 5-fluorouracil schedule and dose intensity. a Southwest Oncology Group and Eastern Cooperative Oncology Group study

CG Leichman;JK Benedetti;MM Zalupski;H Hochster;AF Shields;HJ Lenz;JL Wade;JD Bearden;JS Macdonald Clinical Colorectal Cancer 5(2):119-123

Phase III trial of protracted infusion (PI) vs intermittent high-dose infusion (HDI) 5-fluorouracil (5-FU) in patients (PTS) with disseminated colorectal cancer (DCRC): a Southwest Oncology Group (SWOG) and Eastern Cooperative Oncology Group (ECOG) study.

CG Leichman;J Benedetti;H Hochster;M Zalupski;A Benson;J Macdonald Proc of the American Society of Clinical Oncology 20:125a(#497)